Impact BioMedical Inc. (IBO)
NYSEAMERICAN: IBO · Real-Time Price · USD
1.160
-0.510 (-30.54%)
At close: Dec 20, 2024, 4:00 PM
1.430
+0.270 (23.28%)
After-hours: Dec 20, 2024, 7:57 PM EST
Impact BioMedical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | - | - | 0.05 | - | - | - | |
| Gross Profit | - | - | 0.05 | - | - | - | |
| Selling, General & Admin | 2.02 | 1.76 | 1.12 | 0.99 | 0.38 | 0.18 | |
| Research & Development | 0.48 | 1.15 | 1.23 | 1.08 | 0.51 | 0.34 | |
| Operating Expenses | 3.66 | 4.03 | 3.45 | 3.19 | 0.9 | 0.52 | |
| Operating Income | -3.66 | -4.03 | -3.4 | -3.19 | -0.9 | -0.52 | |
| Interest Expense | -0.92 | -0.44 | -0.46 | -0.3 | - | - | |
| Interest & Investment Income | 0.01 | 0.01 | 0.02 | 0.17 | - | - | |
| Earnings From Equity Investments | - | - | - | - | - | -0.04 | |
| Other Non Operating Income (Expenses) | 5.67 | 0.05 | 0.07 | 0.08 | - | - | |
| EBT Excluding Unusual Items | 1.1 | -4.41 | -3.78 | -3.24 | -0.9 | -0.56 | |
| Merger & Restructuring Charges | - | - | - | - | - | -0.09 | |
| Gain (Loss) on Sale of Investments | - | - | -4.1 | - | - | - | |
| Pretax Income | 1.1 | -4.41 | -7.88 | -3.24 | -0.9 | -0.65 | |
| Income Tax Expense | - | - | -0.62 | -1.4 | -0.08 | - | |
| Earnings From Continuing Operations | 1.1 | -4.41 | -7.26 | -1.85 | -0.81 | -0.65 | |
| Minority Interest in Earnings | 0.06 | 0.07 | 0.2 | 0.55 | 0.22 | 0.2 | |
| Net Income | 1.17 | -4.34 | -7.05 | -1.3 | -0.6 | -0.45 | |
| Net Income to Common | 1.17 | -4.34 | -7.05 | -1.3 | -0.6 | -0.45 | |
| Shares Outstanding (Basic) | 15 | 60 | 70 | 70 | 70 | - | |
| Shares Outstanding (Diluted) | 61 | 60 | 70 | 70 | 70 | - | |
| Shares Change (YoY) | -14.00% | -14.54% | 0.00% | - | - | - | |
| EPS (Basic) | 0.08 | -0.07 | -0.10 | -0.02 | -0.01 | - | |
| EPS (Diluted) | 0.01 | -0.07 | -0.10 | -0.02 | -0.01 | - | |
| Free Cash Flow | -3.1 | -2.87 | -2.52 | -2.03 | -0.9 | -0.61 | |
| Free Cash Flow Per Share | -0.05 | -0.05 | -0.04 | -0.03 | -0.01 | - | |
| Gross Margin | - | - | 100.00% | - | - | - | |
| Operating Margin | - | - | -6808.00% | - | - | - | |
| Profit Margin | - | - | -14102.00% | - | - | - | |
| Free Cash Flow Margin | - | - | -5036.00% | - | - | - | |
| EBITDA | -3.66 | -4.02 | -2.29 | -2.07 | - | - | |
| D&A For EBITDA | 0.01 | 0.01 | 1.11 | 1.11 | - | - | |
| EBIT | -3.66 | -4.03 | -3.4 | -3.19 | -0.9 | -0.52 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.